Eyeworld

Xiidra is the only LFA-1 antagonist approved to treat the signs and symptoms of Dry Eye Disease (DED) 1,3 Xiidra is designed to target the interaction between LFA-1 on T cells and ICAM-1. ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. This interaction is a key mediator of infl ammation, which may contribute to the chronic and sometimes progressive nature of DED and perpetuate the signs and symptoms. 1,2,4,5 In vitro studies have shown that Xiidra may inhibit the recruitment of previously activated T cells, the activation of newly recruited T cells, and the release of pro-infl ammatory cytokines. 1 The exact mechanism of action of Xiidra in DED is not known. 1 Indication Xiidra ® (lifi tegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). Important Safety Information Xiidra is contraindicated in patients with known hypersensitivity to lifi tegrast or to any of the other ingredients. In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. Safety and effi cacy in pediatric patients below the age of 17 years have not been established. BLOCKS REDUCES Xiidra blocks the interaction of ICAM-1 and LFA-1 1 Xiidra may reduce pro-infl ammatory cytokine release 1 Xiidra may inhibit T-cell recruitment and activation 1 INHIBITS For additional safety information, see accompanying Brief Summary of Safety Information on the adjacent page and Full Prescribing Information on Xiidra-ECP.com. References: 1. Xiidra [Prescribing Information]. Lexington, MA: Shire US. 2. TFOS DEWS II Research Subcommittee. Report of the Research Subcommittee of the Tear Film & Ocular Surface Society Dry Eye WorkShop II (2017). Ocul Surf. 2017;15(3):269-649. 3. Food and Drug Administration. Electronic Orange Book. https://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/UCM071436.pdf. Accessed September 1, 2018. 4. Zhong M, Gadek TR, Bui M, et al. Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye. ACS Med Chem Lett. 2012;3(3):203-206. 5. American Academy of Ophthalmology. Dry eye syndrome preferred practice pattern—2013. http://www.aao.org/preferred-practice-pattern/dry-eye-syndrome-ppp--2013. Accessed August 1, 2018. ©2018 Shire US Inc., Lexington, MA 02421. 1-800-828-2088. All rights reserved. SHIRE and the Shire Logo are trademarks or registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affi liates. Marks designated ® and ™ are owned by Shire or an affi liated company. S42271 10/18 XIIDRA MAY DIISRUPT THE INFLAMMATORY CYCLE 1,2 Check it out at Xiidra-ECP.com

• Blank Page
• Blank Page (1)